36
Views
9
CrossRef citations to date
0
Altmetric
Original Article

Combination of Granulocyte Colony-Stimulating Factor and Low-Dose Cytosine Arabinoside Further Enhances Myeloid Differentiation in Leukemia Cells in Vitro

, , , , &
Pages 173-184 | Received 30 Jan 2000, Published online: 01 Jul 2009

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

K. N. Leung, N. K. Mak & M. C. Fung. (2005) Cytokines in the Differentiation Therapy of Leukemia: From Laboratory Investigations to Clinical Applications. Critical Reviews in Clinical Laboratory Sciences 42:5-6, pages 473-514.
Read now

Articles from other publishers (8)

Meiqing Lei, Limin Liu, Zhiming Wang & Depei Wu. (2019) Efficacy of high-dose cytarabine and aclarubicin in combination with G-CSF regimen compared to intermediate/high-dose cytarabine and standard-dose cytarabine induction regimen for non-remission acute myeloid leukemia. Indian Journal of Cancer 56:2, pages 167.
Crossref
Xiaoli Li, Limin Liu, Yanming Zhang, Qi Qu, Yao Yao, Tong Wang, Wenjing Jiao & Depei Wu. (2015) Efficacy of cytarabine, aclarubicin and granulocyte colony-stimulating factor (CAG) regimen compared to FLAG regimen for adult patients with relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia Research 39:11, pages 1201-1206.
Crossref
Limin Liu, Yanming Zhang, Zhengming Jin, Xingxia Zhang, Guangsheng Zhao, Yejun Si, Guoqiang Lin, Aidi Ma, Yingxin Sun, Li Wang & Depei Wu. (2014) Increasing the dose of aclarubicin in low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) can safely and effectively treat relapsed or refractory acute myeloid leukemia. International Journal of Hematology 99:5, pages 603-608.
Crossref
Junichi Kitagawa, Takeshi Hara, Hisashi Tsurumi, Nobuhiro Kanemura, Senji Kasahara, Masahito Shimizu & Hisataka Moriwaki. (2010) Cell Cycle-Dependent Priming Action of Granulocyte Colony-Stimulating Factor (G-CSF) Enhances in vitro Apoptosis Induction by Cytarabine and Etoposide in Leukemia Cell Lines. Journal of Clinical and Experimental Hematopathology 50:2, pages 99-105.
Crossref
Sheng‐Li Xue, De‐Pei Wu, Ai‐Ning Sun & Xiao‐Wen Tang. (2007) CAG regimen enables relapsed or refractory T‐cell acute lymphocytic leukemia patients to achieve complete remission: A report of six cases. American Journal of Hematology 83:2, pages 167-170.
Crossref
Nobuhiro Kanemura, Hisashi Tsurumi, Senji Kasahara, Takeshi Hara, Toshiki Yamada, Michio Sawada, Naoe Goto, Jun‐ichi Kitagawa, Masahito Shimizu, Masami Oyama & Hisataka Moriwaki. (2007) Continuous drip infusion of low dose cytarabine and etoposide with granulocyte colony‐stimulating factor for elderly patients with acute myeloid leukaemia ineligible for intensive chemotherapy. Hematological Oncology 26:1, pages 33-38.
Crossref
K Funato, K Miyazawa, M Yaguchi, A Gotoh & K Ohyashiki. (2002) Combination of 22-oxa-1,25-dihydroxyvitamin D3, a vitamin D3 derivative, with vitamin K2 (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 16:8, pages 1519-1527.
Crossref
K Miyazawa, M Yaguchi, K Funato, A Gotoh, Y Kawanishi, Y Nishizawa, A Yuo & K Ohyashiki. (2001) Apoptosis/differentiation-inducing effects of vitamin K2 on HL-60 cells: dichotomous nature of vitamin K2 in leukemia cells. Leukemia 15:7, pages 1111-1117.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.